Japan's drugmakers aren't any more immune from generic competition than U.S. pharma companies are. Still the country's second- and third-largest drugmakers are predicting sales growth this year, even as low-cost copies drain away sales of their key products. New drugs are coming in to pick up the slack, the companies said.
CEO Deborah Dunsire is retiring from Millennium, the unit Takeda bought about 5 years ago, as Millennium's oncology R&D is rolled up into the parent company's global research organization.
Computer modeling has shed more light on the structure of a protein found clumped together in the neurons of those stricken with Parkinson's disease, opening a path that drug hunters could march down to find new ways of treating the neurological disease.
The anemia drug Omontys triggered serious allergic reactions long before February's recall, The Wall Street Journal reports.
The company struck an $80 million deal to buy back ex-U.S. rights to the short-bowel syndrome drug from Takeda.
In a push to find new targets for central nervous system diseases, which have proved complex to treat, The Scripps Research Institute and Takeda Pharmaceuticals are expanding their research collaboration.
Actos and its potential links to bladder cancer are now on trial. And already, lawyers have brought out incriminating emails, in which Takeda Pharmaceutical executives discuss damage-control plans. It's the first case pitting a patient with bladder cancer against Japan's Takeda, which built Actos into a $4.5 billion product before safety questions took hold. The company faces at least 3,000 similar claims.
Severe hypersensitivity reactions in Omontys patients prompted Affymax and Takeda Pharmaceutical to recall all lots of the anemia drug, designed for use in dialysis patients.
Björklund had been CEO at the Swiss drugmaker Nycomed, until it sold out to Takeda Pharmaceuticals in 2011.
Takeda Pharmaceutical last week nailed down FDA approval for three new diabetes drugs--DPP-4 inhibitors--and it was none too soon, as today's earnings report makes crystal clear.